Gynecologic Oncology Group Specimen Banking

妇科肿瘤组样本库

• 批准号: 7991466
• 负责人: Philip J. DiSaia
• 金额: $ 59.65万
• 依托单位: GYNECOLOGIC ONCOLOGY GROUP
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-15 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7991466
• 关键词: Canada; Cervical; Clinical Trials; Cooperative Human Tissue Network; Data; Data Collection; Discipline; Drug or chemical Tissue Distribution; Enrollment; Grant; Gynecologic; Gynecologic Oncology Group; Improve Access; Institution; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Medical Research; Medicine; Microscopy; Molecular; Monitor; Nucleic Acids; Ovarian; Paper; Pathology; Patients; Peritoneal; Process; Research; Research Personnel; Specimen; Specimen Handling; Technology; Tissue Banking; Tissue Banks; Tissue Microarray; Tissue Procurements; Tissues; Translational Research; United States; base; data exchange; digital; insight; meetings; multidisciplinary; novel therapeutic intervention; novel therapeutics; programs; virtual; web site

DESCRIPTION (provided by applicant): The Gynecologic Oncology Group (GOG) is a premier multidisciplinary, multimodal clinical trial research program investigating new therapeutic approaches in the management of gynecologic malignancies. The GOG Tissue Bank, through the Tissue Utilization Subcommittee of the Committee on Experimental Medicine, is an integral part of this program. Since 2003, the GOG Tissue Bank has received and processed specimens from close to 46,000 patients enrolled at over 250 institutions. The Bank also distributed over 81,000 specimens to 215 investigators, resulting in 122 scientific papers. This is reflective of improved access by investigators to the GOG Tissue Bank via NCI web sites and networking of investigators via the Cooperative Human Tissue Network. The GOG Tissue Bank monitors and modifies its tissue procurement and distribution technologies to meet changing investigator needs. This is evidenced by the introduction of tissue microarray and virtual microscopy technologies during the last grant cycle, Our Specific Aims are; 1. To extend the spectrum of molecular research in gynecologic cancer via expanded procurement of not only ovarian, but also cervical, uterine, primary peritoneal and rare gynecologic malignancies. 2. To enhance biospecimen data collection and exchange with the Statistical Data Center and all participating GOG disciplines and committees to advance translational research and high-impact discoveries. 3. To extend the spectrum of virtual microscopy and digital pathology for gynecologic cancer via expanded participation, use, and functionality of the technology 4. To continue to expand tissue-based technologies including nucleic acid extractions and tissue microarrays (TMAs) to facilitate molecular research. 5. To harmonize with other Cooperative Group Banks through NCI Group Banking Committee initiatives to simplify investigators' access to biospecimens and associated data. RELEVANCE: The Gynecologic Oncology Group (GOG) Tissue Bank receives processes and stores gynecologic cancer specimens from patients enrolled on GOG clinical trials. These specimens are then distributed to investigators across the United States and Canada for use in medical research. The results of this research range from gaining new insights into how cancers develop and progress to the efficacy of new therapeutic regiments.

描述(由申请人提供)：妇科肿瘤学小组(GOG)是一个主要的多学科、多模式的临床试验研究计划，研究妇科恶性肿瘤治疗的新治疗方法。GOG组织银行通过实验医学委员会的组织利用小组委员会，是这一计划不可或缺的一部分。自2003年以来，GOG组织库已经接收和处理了250多个机构登记的近46,000名患者的样本。世行还向215名调查人员分发了81000多份标本，发表了122篇科学论文。这反映了调查人员通过NCI网站访问GOG组织库的情况有所改善，并通过合作人类组织网络建立了调查人员的网络。GOG组织库监测和修改其组织采购和分发技术，以满足不断变化的研究人员的需求。在上一个资助周期中引入了组织微阵列和虚拟显微镜技术，这证明了这一点，我们的具体目标是：1.通过扩大采购不仅是卵巢癌，而且是宫颈、子宫、原发腹膜和罕见的妇科恶性肿瘤，扩大妇科癌症的分子研究范围。2.加强与统计数据中心和全球海洋观测系统所有参与学科和委员会的生物样品数据收集和交流，以促进翻译研究和重大发现。3.通过扩大技术的参与、使用和功能，扩大妇科癌症的虚拟显微镜和数字病理学的范围4.继续扩大以组织为基础的技术，包括核酸提取和组织微阵列(TMA)，以促进分子研究。5.通过NCI集团银行委员会的倡议，与其他合作集团银行协调，简化调查人员获取生物检验品和相关数据的工作。 相关性：妇科肿瘤组(GOG)组织库接收、处理和存储参加GOG临床试验的患者的妇科癌症标本。这些标本随后被分发给美国和加拿大的调查人员，用于医学研究。这项研究的结果范围从对癌症如何发展和进展的新见解到新治疗方案的疗效。